CytomX Therapeutics Hits Day High with Strong 10% Intraday Surge

CytomX Therapeutics, Inc. has experienced a significant uptick in its stock performance, gaining 10.0% on June 29, 2026. The stock reached an intraday high of USD 3.81, marking a notable achievement for the small-cap company in the Pharmaceuticals & Biotechnology sector. In terms of performance metrics, CytomX has shown a remarkable 23.03% increase over the past week, significantly outperforming the S&P 500, which declined by 0.43% during the same period. Over the past year, the stock has surged by 66.22%, while the S&P 500 has returned 20.53%. However, it is important to note that the company has faced challenges, including a substantial decline in net sales of 79.85% reported on March 26, and negative results for the last three consecutive quarters. Despite these hurdles, CytomX's stock has demonstrated resilience, particularly over a three-year horizon, where it has achieved a remarkable 165.25% increase. The company's market capitalization stands at USD 977 million, reflecting its position within the micro-cap segment of the market.